F10 and hemophilia A: Emicizumab (FIXa × FX) exemplifies this modality by mimicking coagulation factor VIII activity and facilitating factor X activation in patients with hemophilia A [242]; (4) Biological barrier transcytosis: Certain bsAbs can traverse physiological barriers by exploiting receptor-mediated transport.